First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial

Journal:

Nature Communications

Published:

2026-02-27

DOI:

10.1038/s41467-026-69622-7

Affiliations:

22

Authors:

21

Go to article

Institutions	Authors	Share
Frankfurt Cancer Institute (FCI), Germany	3.000000	0.14
TUM University Hospital Klinikum rechts der Isar (MRI), Germany	1.000000	0.05
Frankfurt Institute of Clinical Cancer Research (IKF), Germany	1.000000	0.05
University Cancer Center Frankfurt-Marburg (UCT Frankfurt-Marburg), Germany	1.000000	0.05
Charité - University Medicine Berlin, Germany	1.000000	0.05
University Hospital Gießen and Marburg GmbH (UKGM), Germany	1.000000	0.05
Onkologie Ravensburg, Germany	1.000000	0.05
Ulm University Medical Center, Germany	1.000000	0.05
University Medical Centre Mannheim (UMM) at Medical Faculty Mannheim, Uni Heidelberg, Germany	1.000000	0.05
University Medical Center Schleswig-Holstein (UKSH), Germany	1.000000	0.05
Jena University Hospital (UKJ), FSU, Germany	1.000000	0.05
University Hospital Carl Gustav Carus Dresden, TU Dresden, Germany	1.000000	0.05
Onkologicum HOPA MVZ, Germany	1.000000	0.05
University Hospital Tübingen (UKT), Uni Tübingen, Germany	1.000000	0.05
University Hospital of Munich (KUM), LMU, Germany	1.000000	0.05
RKH Klinikum Ludwigsburg, Germany	1.000000	0.05
Hämatologisch-Onkologische Praxis Eppendorf (HOPE), Germany	0.500000	0.02
University Cancer Center Hamburg (UCCH), UHH, Germany	0.500000	0.02
Klinik und Poliklinik für Hautkrankheiten, Universität Greifswald, Germany	0.500000	0.02
Helios Hospital Bad Saarow, Germany	0.500000	0.02
AMEOS Reha Klinikum Ratzeburg, Germany	0.500000	0.02
Agaplesion Markus Hospital, Germany	0.500000	0.02

Interested in Oncology and Carcinogenesis?